GENFIT (GNFT)
(Delayed Data from NSDQ)
$4.09 USD
-0.67 (-14.08%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $4.33 +0.24 (5.87%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
Brokerage Reports
GENFIT S.A. Unsponsored ADR [GNFT]
Reports for Purchase
Showing records 61 - 80 ( 115 total )
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
NASH Weekly: GLP-1 Data in 2Q20 Is Likely to Be Underwhelming
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
As we are three weeks away from JPM Healthcare conference.
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
Healthcare - Yas'' Weekly Recap of Our Key Notes
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
Unlocking the Power of Non-Invasive NASH Diagnosis - Must Read
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
Yas'' Weekly Recap of Our Key Notes and Upcoming Events
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
Join Our Call at 12:30 PM Today to Figure Out POS for RESOLVE-IT
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
Healthcare Expert Call Recap for 2019 in NASH and Liver Disease
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
Why You Can''t Miss Our Four Doc Calls on mRNA, PPAR, Hyperoxaluria, Acromegaly
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
Join our Call Series to Connect the Dots on NASH Biology - Diagnosis
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
Our Holiday Gift: Join Our mRNA, NASH, Acromegaly, Enteric Hyperoxaluria Calls
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
NIS4 Leads the Way for Non-Invasive NASH Dx in T2DM
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y